IL17A and neoplasm: The selective recruitment of CXCR3(+) B cells bridges the pro-inflammatory interleukin 17 response and the polarization of tumorigenic macrophages in the tumor environment, blocking the migration or function of CXCR3(+) B cells may help defeat HCC.